trial on previously untreated RCC

edit

ASCO: VEGF Blocker Active in Metastatic RCC is only phase II but suggests it may also be effective in previously untreated RCC. - Rod57 (talk) 14:57, 10 June 2012 (UTC)Reply

Encouraging results in RCC from a trial in combination with a PD1-inhibitor pembrolizumab

edit

Says 'Unprecedented' 73% Response Rate With Combo in Untreated RCC - suggests due to it being a more selective VEGF inhibitor. These results gained FDA Breakthrough designation for the combination. - Rod57 (talk) 18:03, 19 February 2018 (UTC)Reply